E Fund Management Co. Ltd. Acquires 4,415 Shares of Danaher Co. (NYSE:DHR)

E Fund Management Co. Ltd. grew its holdings in shares of Danaher Co. (NYSE:DHR) by 276.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 6,010 shares of the conglomerate’s stock after acquiring an additional 4,415 shares during the period. E Fund Management Co. Ltd.’s holdings in Danaher were worth $1,390,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Banco Santander S.A. acquired a new stake in shares of Danaher in the third quarter valued at about $683,000. First Citizens Bank & Trust Co. raised its holdings in Danaher by 0.6% during the 4th quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares during the last quarter. Cercano Management LLC lifted its position in shares of Danaher by 11.4% in the 4th quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock worth $46,862,000 after purchasing an additional 20,715 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Danaher by 48.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after purchasing an additional 96,395 shares during the last quarter. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Danaher by 4.8% in the 3rd quarter. Parkside Financial Bank & Trust now owns 3,080 shares of the conglomerate’s stock valued at $764,000 after purchasing an additional 142 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.8 %

Shares of Danaher stock traded up $1.88 on Thursday, hitting $251.43. The company had a trading volume of 1,532,139 shares, compared to its average volume of 2,716,657. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The stock has a 50 day moving average of $248.15 and a 200-day moving average of $233.30. The stock has a market capitalization of $186.23 billion, a price-to-earnings ratio of 42.62, a P/E/G ratio of 3.82 and a beta of 0.83.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the prior year, the firm posted $2.36 EPS. Danaher’s quarterly revenue was down 2.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Danaher Co. will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date is Friday, June 28th. Danaher’s payout ratio is 18.31%.

Analysts Set New Price Targets

DHR has been the topic of several recent analyst reports. Citigroup boosted their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Barclays upped their target price on Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 24th. Bank of America lifted their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Robert W. Baird increased their target price on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 24th. Finally, TD Cowen lifted their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $267.31.

Insider Buying and Selling at Danaher

In related news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now owns 115,995 shares in the company, valued at $28,908,273.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. In the last 90 days, insiders sold 103,984 shares of company stock worth $25,997,094. Insiders own 10.90% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.